SEATTLE, April 3, 2025 /PRNewswire/ -- In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results from the sentinel cohort of ...

The company aims to move cell therapies developed at Fred Hutchinson Cancer… Read More Lumen Bioscience today announced a $16 million Series B round to help support its novel approach to rapid ...

Spirulina under a microscope. Lumen Bioscience researchers engineered spirulina to biomanufacture a natural enzyme that they've shown destroys methanogens, the microbes in cows' rumen that ...

Seattle-based Lumen Bioscience has developed a new spirulina-based drug discovery, manufacturing and delivery platform for highly prevalent diseases that have been difficult to address with ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.